Form 4: Black Diamond Therapeutics Director Acquires Stock Options

Shannon Campbell, a Director at Black Diamond Therapeutics, Inc., acquired 40,000 stock options on June 26, 2026.

Summary

• Director Shannon Campbell acquired 40,000 stock options in Black Diamond Therapeutics, Inc. on June 26, 2026.
• The stock options have an exercise price of $1.71 and an expiration date of June 25, 2036.
• These options are subject to vesting conditions, with full vesting occurring on June 26, 2027, or the issuer's next annual meeting, provided the reporting person continues to serve.
• The reporting person is listed as a Director and not as a 10% owner or officer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director, which is a common practice and does not inherently signal a significant positive or negative development.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition of a significant number of options (40,000) suggests a long-term commitment from the director.

Risks

• The vesting schedule for the stock options means the director will not immediately benefit from them, and continued service is required.
• The value of the stock options is contingent on the future performance of Black Diamond Therapeutics' stock price.

Future Outlook

The future outlook for the stock options is dependent on the company's performance and the director's continued service, with full vesting expected by June 26, 2027, or the next annual meeting.

Industry Context

StockSavvy.ai notes that insider option grants, particularly to directors, are common in the biotechnology sector as a means to align executive interests with shareholder value and incentivize long-term growth, especially for companies in development stages.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive alignment of interests, potentially leading to increased focus on long-term value creation.
• Employees: May view this as a sign of confidence in the company's future, though it directly impacts only the director.
• Management: Reinforces the use of equity-based compensation to incentivize key personnel.

Next Steps

• The director will continue to serve the company.
• The stock options will vest according to the specified schedule.
• The director may exercise the vested stock options upon meeting the vesting conditions.

Key Dates

Keywords

Black Diamond Therapeutics, BDTX, Form 4, Stock Options, Director, Insider Trading, SEC Filing, Equity